Fluorouracil/salicylic acid

Drug Profile

Fluorouracil/salicylic acid

Alternative Names: Actikerall; LAS-41005

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.
  • Class Anti-inflammatories; Antineoplastics; Pyrimidinones; Salicylates
  • Mechanism of Action Keratinocyte inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis

Most Recent Events

  • 14 Sep 2016 Efficacy data from a phase III trial in Actinic Keratosis released by Almirall, S.A.
  • 22 Feb 2016 Launched for Actinic keratosis in Canada (Topical)
  • 01 Sep 2015 Almirall completes a phase III trial in Actinic keratosis in Germany and the UK (NCT02289768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top